References
-
1.
Muendlein A, Lang AH. R462Q Mutation in Prostate Cancer Specimens. Gene Cell Tissue. 2014;1(3). e23730.
-
2.
Haas GP, Delongchamps N, Brawley OW, Wang CY, de la Roza G. The worldwide epidemiology of prostate cancer: perspectives from autopsy studies. Can J Urol. 2008;15(1):3866-71. [PubMed ID: 18304396].
-
3.
Lessick M, Katz A. A genetics perspective on prostate cancer. Urol Nurs. 2006;26(6):454-60. [PubMed ID: 17253080].
-
4.
Ostrander EA, Markianos K, Stanford JL. Finding prostate cancer susceptibility genes. Annu Rev Genomics Hum Genet. 2004;5:151-75. [PubMed ID: 15485346]. https://doi.org/10.1146/annurev.genom.5.061903.180044.
-
5.
Smith JR, Freije D, Carpten JD, Gronberg H, Xu J, Isaacs SD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996;274(5291):1371-4. [PubMed ID: 8910276].
-
6.
Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002;30(2):181-4. [PubMed ID: 11799394]. https://doi.org/10.1038/ng823.
-
7.
Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet. 2002;70(5):1299-304. [PubMed ID: 11941539]. https://doi.org/10.1086/340450.
-
8.
Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 2002;32(4):581-3. [PubMed ID: 12415269]. https://doi.org/10.1038/ng1021.
-
9.
Robbins CM, Hernandez W, Ahaghotu C, Bennett J, Hoke G, Mason T, et al. Association of HPC2/ELAC2 and RNASEL non-synonymous variants with prostate cancer risk in African American familial and sporadic cases. Prostate. 2008;68(16):1790-7. [PubMed ID: 18767027]. https://doi.org/10.1002/pros.20841.